Posts

Showing posts with the label melanoma

Fenbendazole in Melanoma - synergy with VERZENIO - 2025 South Korean paper

Image
2025 Se-Hoon Kim et al - Abemaciclib induces G1 arrest and lysosomal dysfunction in canine melanoma cells: synergistic effects with Fenbendazole. (1) Highlights  Abemaciclib (VERZENIO), a CDK4/6 inhibitor, is well-established for treating hormone receptor-positive and HER2-negative (HR+/HER2−) human breast cancer. Five canine melanoma (skin cancer) cell lines were used to evaluate the antitumor effects of abemaciclib.  Synergistic effects with fenbendazole were evaluated. RESULTS: Abemaciclib induced G1 cell cycle arrest, autophagy (but not apoptosis) Co-treatment with fenbendazole enhanced cytotoxicity and showed synergistic effects within specific dose ranges. Mouse tumors were smaller. mouse body weight remained same (treatment was well tolerated). Synergistic interaction with Fenbendazole suggests a potential combinatorial therapeutic approach for canine melanoma. CONCLUSION: This study showed that a new generation Targeted therapy for breast cancer (abemaciclib) or VER...

Archive

Show more